SNX-5422

SNX-5422 (PF-04929113), a prodrug of SNX-2112, is an orally active Hsp90 inhibitor, with a Kd of 41 nM, and also induces Her-2 degradation, with an IC50 of 37 nM.

Product Specifications

CAS Number

[908115-27-5]

Product Name Alternative

PF-04929113

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

HSP

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/PF-04929113.html

Concentration

10mM

Purity

96.52

Solubility

DMSO : 32.5 mg/mL (ultrasonic)

Smiles

FC(F)(C1=NN(C2=CC(N[C@@H]3CC[C@H](CC3)OC(CN)=O)=C(C=C2)C(N)=O)C(CC(C)(C4)C)=C1C4=O)F

Molecular Formula

C25H30F3N5O4

Molecular Weight

521.53

Precautions

H302, H315, H319, H335

References & Citations

[1]Huang KH, et al. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem. 2009 Jul 23;52 (14) :4288-305|[2]Chandarlapaty S, et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res. 2008 Jan 1;14 (1) :240-8.|[3]Kim SH, et al. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells. Endocrine. 2016 Feb;51 (2) :274-82.